[36], in a real-world cohort treated with GLP-1 RAs including exenatide, observed a mean BW loss of 2.5 kg and a BMI reduction of 0.9 kg/m without a significant change in intrahepatic lipid content, reflecting variability in hepatic responses across populations
What does not work is balancing a vial on your knee while sitting on the couch
Yes, they suppress your appetite
Ndumele CE, Rangaswami J, Chow SL, Neeland IJ, Tuttle KR, Khan SS, et al
Patients who do not have diabetes or only take semaglutide for weight loss generally do not need to worry about hypoglycemia during exercise
Early results from ongoing clinical studies are indicating the GLP-1 medications may successfully treat numerous other conditions including non-alcoholic fatty liver disease (known as metabolic dysfunction-associated steatohepatitis or MASH), sleep apnea, heart failure, diabetic kidney disease and Alzheimers disease